PARP1 and cancer: Clinical development of PARPi started in 2003 and focused on two strategies: utilizing PARPi in combination with other drugs in a range of solid malignancies or using PARPi monotherapy in specific cancer types with features (like impairment of DNA-damage repair systems alternative to the PARP-dependent ones) that would be predicted to be highly sensitive to PARP inhibition.